Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.

J Int Med Res · 2020 · PMC7607055 · PMID 31885349

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

22 In the present study, patients treated with erlotinib had a trend toward better clinical ORR, pathological response rate, and OS; however, given the small size of our study cohort, these results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.